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ABSTRACT  
 Congenital thrombotic thrombocytopenic purpura (CTTP) is a rare disease due to 
mutations in genes that reduce the production of ADAMTS 13 (Metalloproteinease). 
Metalloproteinease deficiency causes large multimeres of Von Willebrand factor VWF not going 
to broken and result in anemia and thrombocytopenia (Microangiopatic hemolytic anemia) with 
renal involvement.  
The case is a 9 years old boy who suffers from anemia, thrombocytopenia since age three 
with some courses of hematuria, BUN and creatinine rising period. He had different diagnosis 
such as ITP (Immune thrombocytopenic purpura), Fanconi anemia, autoimmune hemolytic 
anemia, Evans syndrome and has been taken various immunosuppressive therapy and frequent 
blood transfusion. After 6 years following HUS like crisis and due to congenital deficiency of 
ADAMs13 and normal antibody against it he was diagnosed as a CTTP and treated with regular 
injections FFP . 
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_____________________________________________________________________________________ 
INTRODUCTION 
   Congenital thrombotic 
thrombocytopenic purpura (CTTP) is a 
syndrome due to reversible platelet 
aggregation and cause micro-vascular 
ischemia in various organs. 
Thrombocytopenia, microangiopathic 
hemolytic anemia, neurologic symptoms, 
fever and renal dysfunction are seen in most 
patients and without treatment, mortality is 
90%. There are two main types of TTP acute 
acquired is type I and type II is a rare 
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hereditary recurrent disease. Type I is seen 
with no particular reason, idiopathic , or 
followed by a secondary bacterial infections, 
viral, pregnancy , collagen vascular disease, 
pancreatitis and certain drugs.
1
  
 In normal conditions, ADAMTS 13 
as an Metalloproteinase is a VWF (VWF-
cleaving) agent. It breaks and divides large 
multimeres to small one. In the absence of 
ADAMTS 13 activity large VWF formed 
and with production of fibrin within the 
vessels causing TTP. Reduced ADAMTS 13 
activity is an inherited chronic and recurrent 
condition due to mutations in the gene for 
ADAMTS 13.It is transmitted by autosomal 
recessive trait.
2,3
 Cell culture studies have 
shown that the basic physiopathology of the 
hereditary TTP is protein secretion inability 
and its catalytic inactivity by deficiency of 
ADAMTS 13.
 4
Acquired and acute type 
often occurs in adults due to the production 
of IgG auto-antibodies against          
ADAMTS 13. 
5
  
   TTP relatively is rare and occurs 4 
to 5 per million per year and is more 
common in female.
6
 Congenital form 
constitute 1% of the total TTP 
7
 and 
characterized by microangiopathic 
hemolytic anemia, often with fever, 
thrombocytopenia, renal and neurological 
disorders.
8
 Detection of the reduced activity 
of ADAMTS 13 in the absence of anti 
ADAMTS 13 antibodies lead to diagnosis.
3
 
Congenital TTP is well known Upshaw-
Schulman syndrome too and may be 
symptomatic at birth or in early childhood 
and rarely will be asymptomatic till 
adulthood, the severity of the symptoms is 
highly variable. Congenital TTP can be 
confused with chronic ITP or Evans 
syndrome.
9
 Treatment of congenital TTP is 
FFP transfusions to replace the protein 
ADAMTS 13 in long period empirically 
almost every few weeks to a month. 
9, 10
  
   In acquired type because of inhibitor 
antibodies, plasma exchange is required to 
remove the inhibitor.
8
 ADAMTS13 
inhibitors can be identified in most acquired 
cases but in Hemolytic - uremic syndrome 
(HUS) cannot be detected.
 12, 11
 Mutations in 
factor H, a regulator of the complement 
alternative pathway and factor I mutations 
which is a complement inhibitor cause 
microangiopathic hemolytic anemia and 
atypical HUS. 
13-16
 Due to the rarity of 
congenital TTP and similarity of its 
symptoms with other common diseases, 
diagnosis is often delayed for long periods. 
The aim of this presentation is to bring 
attention of physicians to this rare condition 
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to prevent delayed and misdiagnosis of this 
condition.  
CASE REPORT  
A 9-years-old boy who presented for 
the first time in 3 years old with 
thrombocytopenia. After six months anemia 
was added to clinical findings. Anemia was 
hypochrome and macrocytic with corrected 
retic count 2.5%, B12 and folic acid blood 
levels were normal. The direct and indirect 
Coombs were negative, liver enzymes and 
urea, creatinine and LDH were normal but 
(Alkaline phosphatase) ALP has clearly 
increased. Initial diagnosis was ITP and 
patients was treated with prednisone but 
with a drop in hemoglobin and cytopenia 
diagnosis changed to Fanconi anemia and 
Oxymetholone added to therapy.  
Abdominal ultrasound and blood 
tests for hepatitis C, and EBV (Epstein-Barr 
virus) were normal. Evaluation for SLE and 
ANA (Antinuclear antibody) and Anti ds 
DNA were normal. One-year patient was 
treated with CORTICOSTEROIDS, 
CYCLOPHOSPHAMIDE, 
AZATHIOPRINE, METHOTREXATE 
frequent blood and platelet transfusions 
because of drop in hemoglobin (up to 5.9) 
and platelets (below 10,000) counts. Bone 
marrow aspiration in frequents samples were 
normal.  
The patient found microscopic 
hematuria and Burr cell and Helment cell in 
the peripheral blood smear were reported. 
Reticulocyte increased up to 18% simetimes. 
Serum ferritin levels (Prothrombin time) PT, 
(Partial thromboplastin time) PTT, G6PD 
(Glucose - 6 - phosphatase dehydrogenase) 
and hemoglobin electrophoresis were 
normal. Urea was increased coincidentally 
with hematuria during the second year of 
disease. Because of positive results of 
coomb’s test, panel test is done. The panel 
showed positive antibody to Anti-E/Anti-
c/Anti-fya and positive direct Coombs test 
for Anti-IgG-c3b.  
Because of the frequent findings of 
thrombocytopenia and platelet transfusions 
and weekly needs of the platelets transfusion 
Evans syndrome was considered again., 
reevaluations of lupus, hepatitis B, hepatitis 
C, HIV ,BM re-aspiration, Spiral chest and 
abdominal CT scan were normal. In the 
fourth year of illness due to lack of response 
to CORTICOSTEROIDS, 
CYCLOSPORINE, AZATHIOPRINE, 
DANAZOL, and RITUXIMAB was started. 
Following the injection patient showed 
gastrointestinal bleeding and further increase 
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in urea (130), creatinine (8.3), with 
increased blood pressure and hematuria. 
With probably ATN due to hemolysis 
patient was treated with pulse 
methylprednisolone, IVIG (Intravenous 
immunoglobulin) and plasmapheresis. 
Hematuria and nonnephrotic proteinuria 
were constant findings in patient.  
Until the fifth year of the disease (8 
years old age) because of the lack of correct 
diagnosis all medications were discontinued, 
and blood products were limited just in 
bleeding conditions if needed. Gradually the 
need of patient to blood products 
diminished. However, patient found new 
episode of hematuria hypertension and 
increased urea and creatinine again. Because 
of lack of blood products transfusion ATN 
was not considered, and due to fragmented 
RBC in PBS, microangiopathic hemolytic 
anemia, HUS and TTP were evaluated.  
Normal I and B factors with low 
ADAMTS 13 clearly below the normal 
range 20ng/ml (630-850) and normal IgG 
auto antibodies against ADAMTS 13 
resulted in diagnosis of congenital TTP. 
Amlodipine and atenolol are discontinued 
within 4 months. With serial FFP 
transfusion hemoglobin and platelets are in 
normal range. The patient now has the 
history of seven years of disease (10 years 
old) and stay with his daily normal life with 
FFP infusion every 18 days.  
DISCUSSION  
 TTP is a life-threatening multi-
system disease characterized with of 
microangiopathic hemolytic anemia, fever, 
thrombocytopenia, renal failure and 
neurological disorders. Platelet-rich 
thrombosis is caused kidney failure and 
nerve damage. Diminished 
metalloproteinase activity in break down 
VWF multimeres is the pathophysiology of 
TTP. (8).  
Lack of renal and neurological 
findings during early course of disease in 
this patients lead to delayed in diagnosis. At 
first ITP and then with adding leukopenia 
other diseases such as autoimmune 
hemolytic anemia, Evans syndrome, Fanconi 
anemia were considered. After correct 
diagnosis, and holding of blood transfusions 
and immunosuppressive drugs leukopenia 
disappeared and coomb’s changed to 
normal.  
In thrombocytopenia and 
microangiopathic hemolytic anemia with 
negative comb’s and elevated LDH, CTTP 
should be considered. Many patients do not 
show renal and neurologic symptoms (17, 
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18) After 5 years' anemia and 
thrombocytopenia by reducing the infusion 
of blood products and stopping the 
medications patients Coombs changed to 
normal. This result is not compatible with 
Evans and autoimmune hemolytic anemia 
17
.  
 With sustained thrombocytopenia, 
anemia, hematuria, and the presence of Burr 
cells in peripheral blood and 
microangiopathic hemolytic anemia in a 
patient's blood smear, HUS and TTP are 
probable diagnosis. Because of frequent 
relapsing of disaese and severe deficiency of 
ADAMS 13 which is not common in HUS 
(8) and on the other hand, normal factors of 
H and I exclude HUS, low ADAMTS 13 
activity with normal IgG-type 
autoantibodies against ADAMTS 13 
suggests CTTP, which explain anemia, 
thrombocytopenia, hematuria, and increased 
urea, creatinine, and blood pressure of the 
patient. (18) One year therapy with FFP (15 
cc/kg every 18 day) changed the 
thrombocytopenia proteinuria and 
hypertension of patient,although heamturia 
occurs occasionally.  
 We recommend that in every patient 
with thrombocytopenia and hemolytic 
anemia with unknown origin and poor 
response to therapy, CTTP should be 
considered, it prevents complications and 
more additional unnecessary modality of 
therapy.  
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